CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody

CD19 is a B cell–specific antigen expressed on chronic lymphocytic leukemia (CLL) cells but to date has not been effectively targeted with therapeutic monoclonal antibodies. XmAb5574 is a novel engineered anti-CD19 monoclonal antibody with a modified constant fragment (Fc)–domain designed to enhance...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Awan, Farrukh T., Lapalombella, Rosa, Trotta, Rossana, Butchar, Jonathan P., Yu, Bo, Benson, Don M., Roda, Julie M., Cheney, Carolyn, Mo, Xiaokui, Lehman, Amy, Jones, Jeffrey, Flynn, Joseph, Jarjoura, David, Desjarlais, John R., Tridandapani, Susheela, Caligiuri, Michael A., Muthusamy, Natarajan, Byrd, John C.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Hematology 2010
Θέματα:
Lymphoid Neoplasia
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2826232/
https://ncbi.nlm.nih.gov/pubmed/19965644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-229039
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια